mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway

Cell Growth and Differentiation

Volumn 9, Issue 1, 1998, Pages 79-84

  Chang, Young Chae ^a   Lee, Yun Sik ^a   Tejima, Tazuko ^a   Tanaka, Keiji ^b   Ornura, Satoshi ^c   Heintz, Nicholas H ^d   Mitsui, Youji ^a   Magae, Junji ^a  

^a NATL INST BIOSCI HUM TECHNOL   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c KITASATO INSTITUTE   (Japan)

^d UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; POLYUBIQUITIN; PROTEASOME; PROTEIN BAX; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; UBIQUITIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DNA DAMAGE; HELA CELL; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; TUMOR SUPPRESSOR GENE;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CELL DIVISION; CELL LINE; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; HUMANS; HYDROLYSIS; LEUPEPTINS; MULTIENZYME COMPLEXES; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINS;

EID: 0031985007     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
2. Levine, A. J., Momand, J., and Finlay, C. A. Thep53 tumour suppressor gene. Nature (Lond.), 35 J: 453-456, 1991.
3. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
4. Kastan, M. B., and Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is detective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
5. Lu, X., and Lane, D. P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell, 75: 765-778, 1993.
6. Debbas, M., and White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev., 7: 546-554, 1993.
7. Wu, X., and Levine, A. J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3602-3606, 1994.
8. waf 1/CIP 1. Genes Dev., 8: 2817-2830, 1994.
9. Ko, L. J., and Prives, C. p53: puzzle and paradigm. Genes Dev., 10: 1054-1072, 1996.
10. El-Diery, W. S. Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediation of p53 tumor suppression. Cell, 75: 817-825, 1993.
11. Gu, Y., Turck, C. W., and Morgan, D. O. Inhibition of cdk2 activity in vivo by an associated 20K regulatory subunit. Nature (Lond.), 366: 707-710, 1993.
12. Harper, J. W., Adami, G. R., Wei, N., Keyomaarsi, K., and Elledge, S. J. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
13. Xiong, Y., Hannon, G. J., Zhang, H. Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
14. Wu, X., Bayle, H., Olson, D., and Levine, A. L. The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7: 1126-1132, 1993.
15. Barak, Y., Juven, T., Hoffner, R., and Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J., 12: 461-468, 1993.
16. Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D., and Levine A. J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. USA, 90: 11623-11627, 1993.
17. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. L. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
18. Chen, J., Wu, X., Lin, J., and Levine, A. J. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol., 16: 2445-2452, 1996.
19. Haupt, Y., Barak, Y., and Oren, M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J., 15: 1596-1606, 1996.
20. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80: 293-299, 1995.
21. Yin, X-M., Oltvai, Z. N., and Korsmeyer, S. J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature (Lond.), 369: 321-323, 1994.
22. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
23. Xiang, J., Chao, D. T., and Korsmeyer, S. J. Bax-induced cell death may not require interteukin 1/3-converting enzyme-like proteases. Proc. Natl. Acad. Sci. USA, 93: 14559-14563, 1996.
24. Man, J., Sabbatini, P., Perez, D., Rao, L., Modha, D., and White, E. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev., 10: 461-477, 1996.
25. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
26. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. mdm2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.
27. Kubbatat, M. H. G., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by mdm2. Nature (Lond.), 387: 299-303, 1997.
28. Goldberg, A. L. The mechanism and function of ATP-dependent proteases in bacterial and animal cells. Eur. J. Biochem., 203: 9-23, 1992.
29. Hershko, A., and Ciechanover, A. The ubiquitin system for protein degradation. Annu. Rev. Biochem., 61: 761-807, 1992.
30. Coux, O., Tanaka, K and Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem., 65: 801-847, 1996.
31. Goltzer, M., Murray, A. W., and Kirschner, M. W. Cyclin is degraded by the ubiquitin pathway. Nature (Lond.), 349: 132-138, 1991.
32. Clurman, B. E., Sheaff, R. J., Thress, K., Groudine, M , and Roberts, J. M. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev., 10: 1979-1990, 1996.
33. Seufert, W., Futcher, B., and Jentsch, S. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Nature (Lond.), 373: 78-83, 1995.
34. Maki, C. G., Huibregtse, J. M., and Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res., 56: 2649-2654, 1996.
35. WAF1/CIP1 expression. Biochem. Biophys. Res. Commun., 227: 564-569, 1996.
36. Pagano, M . Tam, S. W., Theodoras, A. M., Beer-Romero, P., Sal, G. D., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Washington DC), 269: 682-685, 1995.
37. Ciechanover, A., DiGiuseppe, A. J., Bercovich, B., Orian, A., Richter, J. D., Schwartz, A. L., and Brodeur, G. M. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc. Natl. Acad. Sci. USA, 88: 139-143, 1991.
38. Treier, M., Staszewski, L. M., and Bohmann, D. Ubiquitin-dependent c-jun degradation in vivo is mediated by the 8 domain. Cell, 78: 787-798, 1994.
39. Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell, 78: 773-785, 1994.
40. Rolfe, M., Beer-Romero, P., Glass, S., Eckstein, J., Berdo, I., Theodoras, M., Pagano, M., and Draetta, G. Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). Proc. Natl. Acad. Sci. USA, 92: 3264-3268, 1995.
41. Scheffner, M., Huibregtse, J. M., and Howley, P. M. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc. Natl. Acad. Sci. USA, 91: 8797-8801, 1991.
42. Hateboer, G., Kerkhoven, R. M., Shvarts, A., Bernards, R., and Beijersbergen, R. L. Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev., 10: 2960-2970, 1996.
43. Hofmann, F., Martelli, F., Livingston, D. M., and Wang, Z. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev., 10: 2949-2959, 1996.
44. Shinohara, K., Tokioka, M., Nakano, H., Tone, S., Ito, H., and Kawashima, S. Apoptosis induction resulting from proteasome inhibition. Biochem. J., 317: 385-388, 1996.
45. Drexler, H. C. A. Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad Sci. USA, 94: 855-860, 1997.
46. Imajoh-Ohmi, S., Kawaguchi, T., Sugiyama, S., Tanaka, K., Omura, S., and Kikuchi, H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem. Biophys. Res. Commun., 217: 1070-1077, 1995.
47. Grimm, L. M., Goldberg, A. L., Poirier, G. G., Schwartz, L. M., and Osbome, B. A. Proteasomes play an essential role in thymocytes apoptosis. EMBO J., 15: 3835-3844, 1996.
48. Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., and Goldberg, A. L. Inhibition of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 78: 761-771, 1994.
49. Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., and Schreiber, S. L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (Washington DC), 268: 726-731, 1995.
50. Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., Vogelstein, B., and Friend, S. H. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol., 10: 5772-5781, 1990.
51. Michieli, P., Chedid, M., Lin, D., Peirce, J. H., Mercer, W. E., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
52. Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., and Jacks, T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev., 9: 935-944, 1995.
53. Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D., and Lassar, A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Washington DC). 267: 1018-1021, 1995.
54. CIP1 in muscle and other terminally differentiating cells. Science (Washington DC), 267: 1024-1027, 1995.
55. Canman, C. E., Gilmer, T. M., Courts, S. B., and Kastan, M. B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev., 9: 600-611, 1995.
56. Haldar, S., Jena, N., and Croce, C. M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA, 92: 4507-4511, 1995.
57. Milbrandt, J. D., Heintz, N. H., White, W. C., Rothman, S. M., and Hamlin, J. L. Methotrexate-resistant Chinese hamster ovary cells have amplified a 135-kilobase-pair region that includes the dihydrofolate reductase gene. Proc. Natl. Acad. Sci. USA, 78: 6042-6047, 1981.
58. Magae, J., Wu, C-L, Illenye, S., Harlow, E., and Heintz, N. H. Nuclear localization of DP and E2F transcription factors by heterodimeric partners and retinoblastoma protein family members. J. Cell Sci., 109: 1717-1726, 1996.
59. Omura, S., Fujimoto, T., Otoguro, K., Matsuzaki, K., Moriguchi, R., Tanaka, Y., and Sasaki, Y. Lactacystin, a novel microbial metabolite, induces neurite-genesis of neuroblastoma cells. J. Antibiot., 44: 113-116, 1991.